Study of IBI3016 in People With Mild or Moderate Hypertension Patients
ConditionHypertension
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorInnovent Biologics (Suzhou) Co. Ltd.
About this trial
A Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and pharmacodynamic characteristics of a single subcutaneous dose of IBI3016 in Chinese patients with mild to moderate hypertension.
Eligibility criteria
Qualifiers
Signed informed consent.
Males or females aged 18 to 75 years. 3 Diagnosed primary hypertension who have not been taking anti-hypertensive medication within 4 weeks prior to informed consent.
Disqualifiers
Known history of secondary hypertension.
Orthostatic hypotension.
Laboratory parameter assessments outside of range at screening：
Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) > 2× Upper Limit of Normal (ULN)
Trial design
Treatments tested in this trial
- IBI3016
- Placebo
Treatment groups
30 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov